Recursion Pharmaceuticals

Recursion Pharmaceuticals Revenue per Employee

The Revenue per Employee of Recursion Pharmaceuticals (RXRX) as of Nov 12, 2026 is 124,468.33 USD. In the previous year, Revenue per Employee was 98,065.00 USD — a change of 26.92% (higher).

Revenue per Employee

124,468.33USD

YoY

26.92%

Last updated:

Revenue per Employee of Recursion Pharmaceuticals is 2025 124,468.33 USD. Revenue per Employee of Recursion Pharmaceuticals was 2024 98,065.00 USD. It decreases by 26.92% higher compared to the previous year.

The Recursion Pharmaceuticals Revenue per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Employee
Date
Revenue per Employee
Jan 1, 2019
2,851.67 USD
Jan 1, 2020
5,688.33 USD
Jan 1, 2021
16,666.67 USD
Jan 1, 2022
66,135.00 USD
Jan 1, 2023
73,126.67 USD
Jan 1, 2024
98,065.00 USD
Jan 1, 2025
124,468.33 USD
The Recursion Pharmaceuticals Revenue per Employee history
YEARRevenue per EmployeeYoY
124,468.33USD+26.92%
98,065.00USD+34.10%
73,126.67USD+10.57%
66,135.00USD+296.81%
16,666.67USD+193.00%
5,688.33USD+99.47%
2,851.67USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Revenue per Employee of Recursion Pharmaceuticals is 124,468.33 USD in 2025.

Revenue per Employee of Recursion Pharmaceuticals changed from 98,065.00 USD to 124,468.33 USD, representing a 26.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Employee Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Revenue per employee measures workforce productivity by dividing total revenue by the number of employees. Higher values indicate more efficient operations.

Revenue per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Revenue per Employee's Recursion Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals